Gautam Reddy, MD
Gastroenterology · Valley Stream, NYNPI 1235158585
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $63,945 of the $89,397 with a category attached, or 71.5%. E.r. Squibb & Sons, L.L.C. accounts for 69.3% of it on its own, with 35 other manufacturers making up the rest. Reporting peaked in 2022 at $38,139 and has fallen 88.6% since, to $4,362 in 2025. Among gastroenterology clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 783 payments — averaging $114.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$62K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$8K
- AbbVie$6K
- Bristol Myers Squibb$4K
- Sanofi$1K
- Ardelyx, Inc.$940
- plus $8K from 30 others
What the payments were for
- Consulting fees$1,5002%
- Speaking & faculty fees$63,94572%
- Travel & lodging$1,8262%
- Food & beverage$22,06925%
- Education$570%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 45 | $61,987 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 89 | $7,875 |
| AbbVie(2 entities) | 228 | $5,825 |
| Bristol Myers Squibb | 65 | $3,541 |
| Sanofi | 31 | $1,037 |
| Ardelyx, Inc. | 37 | $940 |
| Takeda Pharmaceuticals U.S.A., Inc. | 47 | $858 |
| Pfizer | 37 | $738 |
| Ironwood Pharmaceuticals, Inc | 13 | $646 |
| Nestle Healthcare Nutrition Inc. | 10 | $616 |
| Madrigal Pharmaceuticals | 9 | $610 |
| QOL Medical, LLC | 17 | $547 |
| Johnson & Johnson(2 entities) | 23 | $533 |
| Redhill Biopharma Inc. | 16 | $407 |
| Braintree Laboratories, Inc. | 12 | $398 |
| Lilly USA, LLC | 20 | $339 |
| Ferring Pharmaceuticals Inc. | 15 | $317 |
| Intercept Pharmaceuticals, Inc. | 8 | $289 |
| Celltrion USA Inc. | 4 | $286 |
| Intra-sana Laboratories | 5 | $236 |
| Phathom Pharmaceuticals, Inc. | 8 | $220 |
| Gilead | 9 | $191 |
| Merck | 9 | $176 |
| Dova Pharmaceuticals | 1 | $131 |
| Vivus LLC | 6 | $127 |
| Boston Scientific | 1 | $126 |
| Evoke Pharma, Inc. | 5 | $99 |
| Exact Sciences | 2 | $60 |
| Ipsen Biopharmaceuticals, Inc | 2 | $53 |
| W. L. Gore & Associates, Inc. | 2 | $50 |
| Cumberland Pharmaceuticals, Inc. | 2 | $35 |
| Novo Nordisk | 1 | $27 |
| Concordia Pharmaceuticals Inc. | 1 | $24 |
| AstraZeneca | 1 | $21 |
| Alfasigma USA, Inc. | 1 | $19 |
| Shionogi Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$89,397 in reported general payments places this provider in the 90th percentile of 1,682 gastroenterology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 23 | $379,372 |
| SimponiGolimumab | 12 | $97,350 |
| XifaxanRifaximin | 17 | $91,571 |
| LinzessLinaclotide | 67 | $71,757 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 164 | $9,554 |
| MovantikNaloxegol Oxalate | 11 | $9,426 |
| Mesalamine | 12 | $7,452 |
| ClenpiqSod Picosulf/Mag Ox/Citric Ac | 34 | $5,799 |
| Pantoprazole Sodium | 379 | $4,727 |
| Omeprazole | 355 | $4,564 |
| Ursodiol | 11 | $2,642 |
| Lubiprostone | 15 | $2,101 |
| Dicyclomine Hcl | 53 | $1,689 |
| Famotidine | 99 | $1,275 |
| CholestyramineCholestyramine (With Sugar) | 18 | $1,176 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonSimponi | $533 | $97,35012 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $7,875 | $91,57117 claims |
| AbbVieLinzess | $5,825 | $71,75767 claims |
| Redhill Biopharma Inc.Movantik | $407 | $9,42611 claims |
| Ferring Pharmaceuticals Inc.Clenpiq | $317 | $5,79934 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,682 gastroenterology providers in New York.
Other gastroenterology in Valley Stream
- David Carr LockeNew York$2M
- Arthur KornbluthNew York$1.9M
- Maya SrivastavaWilliamsville$1.8M
- Melissa PalmerPlainview$1M
- Sonal KumarNew York$1M
- David PoppersNew York$939K
- Ellen ScherlNew York$857K
- Bruce SandsNew York$810K
- Jean Frederick ColombelNew York$786K
- Seth GrossNew York$624K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.